Though our work identified TG5 as a therapeutic target for SCA1, the potential side effect of TG5 inhibition needs to be carefully evaluated given that missense mutations in one allele of TGM6 (one of the transglutaminase paralogs) have been seen in families with SCA35 (35). This evidence concerns the gene TGM6 and spinocerebellar ataxia type 35.